AI Summary
Immunocore reports updated Phase 1/2 results for brenetafusp in heavily pretreated melanoma, with 6-month OS of 87%, DCR 52%, and ORR 12% in 66 patients. The 160 mcg dose shows stronger efficacy signals and is selected for the Phase 3 PRISM-MEL-301 trial with nivolumab in first-line disease. Safety remains manageable, and combination with pembrolizumab may offer additional gains, reinforcing the program’s upside potential.
Sentiment Rationale
Positive detail on a 160 mcg dose and Phase 3 readiness could lift sentiment and set the stage for a data-driven re-rating if PRISM-MEL-301 reads out favorably; risk remains given early-stage data and competition in melanoma immunotherapy.
Trading Thesis
Positive ASCO data support near-term upside for IMCR if Phase 3 validates 160 mcg and combos within 12–24 months.
Market-Moving
- 160 mcg dose selected for Phase 3 PRISM-MEL-301 (NCT06112314).
- ASCO data show durable signals in PD-1 resistant subgroups.
- Combination with nivolumab/pembrolizumab indicates potential first-line gains.
- Event timing around ASCO 2026 presentations could spark volatility.
Key Facts
- 66 patients treated with brenetafusp monotherapy; 6-month OS at 87%.
- DCR 52% and ORR 12% in heavily pretreated HLA-A*02:01 melanoma.
- 160 mcg dose nets higher efficacy; supports 160 mcg in Phase 3 PRISM-MEL-301.
- Safety: CRS 56% (mostly low grade); similar safety at 40 vs 160 mcg.
- Brenetafusp ± pembrolizumab shows higher ORR/DCR; PD-1 resistance still present.
Companies Mentioned
- Immunocore Holdings plc (IMCR): ASCO data bolster brenetafusp (IMC-F106C); potential Phase 3 readout impact on valuation.
- Merck & Co (MRK): Pembrolizumab is evaluated in combination; potential uplift to IMCR's combo strategy.
- Bristol Myers Squibb (BMY): Nivolumab is partner in 1L trials; positive combo data could influence anti-PD-(L)1 landscape.
- Regeneron Pharmaceuticals (REGN): Relatlimab (LAG-3) appears in trial context; potential indirect implications for ImmTAC combos.
- Sanofi (SNY): Co-developer of relatlimab with Regeneron; relevance to LAG-3 combination strategies.
- KIMMTRAK (IMCgp100) (IMCR): Branded ImmTAC product referenced; ongoing franchise considerations amid new data.
Research Analysis
Category: Research Analysis. The release presents clinical efficacy/safety data from a Phase 1/2 program and its implications for a Phase 3 trial, fitting a research-focused update with potential valuation implications for IMCR.